Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
In November 2023, Bayer announced that it was withdrawing copanlisib from the US market.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).